Nexagon® (lufepirsen) High Dose Concentration + Nexagon® (lufepirsen) Low Dose Concentration + Vehicle + Open-label Nexagon® (lufepirsen)

Phase 2Terminated

1 views this week 0 watching💤 Quiet

Interest: 24/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Corneal Persistent Epithelial Defect

Conditions

Corneal Persistent Epithelial Defect

Trial Timeline

Jun 30, 2020 → Feb 7, 2022

NCT ID

NCT04081103

About Nexagon® (lufepirsen) High Dose Concentration + Nexagon® (lufepirsen) Low Dose Concentration + Vehicle + Open-label Nexagon® (lufepirsen)

Nexagon® (lufepirsen) High Dose Concentration + Nexagon® (lufepirsen) Low Dose Concentration + Vehicle + Open-label Nexagon® (lufepirsen) is a phase 2 stage product being developed by Glaukos for Corneal Persistent Epithelial Defect. The current trial status is terminated. This product is registered under clinical trial identifier NCT04081103. Target conditions include Corneal Persistent Epithelial Defect.

What happened to similar drugs?

3 of 4 similar drugs in Corneal Persistent Epithelial Defect were approved

Approved (3) Terminated (1) Active (0)

✅0.3% hypromelloseNovartisApproved

✅Mycophenolate Mofetil 2x 1gRocheApproved

✅loteprednol etabonate 0.25% ophthalmic suspensionKala PharmaceuticalsApproved

❌riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system + placebo: 0.0% riboflavin ophthalmic solution with the KXL systemGlaukosPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04081103	Phase 2	Terminated	Jun 30, 2020	Feb 7, 2022	Corneal Persistent Epithelial Defect

Competing Products

12 competing products in Corneal Persistent Epithelial Defect

See all competitors

Product	Company	Stage	Hype Score
DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solution	Santen Pharmaceutical	Phase 2	35
Vehicle Ophthalmic Solution + Omaveloxolone Ophthalmic Suspension 0.5% + Omaveloxolone Ophthalmic Suspension 1%	AbbVie	Phase 2	35
0.3% hypromellose	Novartis	Approved	43
Mycophenolate Mofetil 2x 1g	Roche	Approved	43
Subconjunctival aflibercept	Regeneron Pharmaceuticals	Phase 1	21
riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system + placebo: 0.0% riboflavin ophthalmic solution with the KXL system	Glaukos	Phase 3	29
lufepirsen high dose + Vehicle + lufepirsen low dose	Glaukos	Phase 2	39
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL + Placebo	Oculis Holding AG	Phase 2	29
DT-168	Design Therapeutics	Phase 2	36
KPI-012 + KPI-012 Vehicle	Kala Pharmaceuticals	Phase 2	17
loteprednol etabonate 0.25% ophthalmic suspension	Kala Pharmaceuticals	Approved	33
QR-504a	ProQR	Phase 1	11